|
Oct 30
|
Indivior Highlights Growing Body of Data on SUBLOCADE® (buprenorphine once-monthly extended-release injection) Helping Patients Achieve Long-Term Recovery from Opioid Use Disorder during Substance Abuse Prevention Month
|
|
Oct 12
|
Indivior price target lowered to $16 from $20 at Craig-Hallum
|
|
Oct 11
|
Indivior PLC (INDV) Q3 2024 Earnings Call Highlights: Navigating Competitive Pressures and ...
|
|
Oct 10
|
Indivior Cuts 2024 Outlook As Competition And Market Pressures Weigh On SUBLOCADE: Details
|
|
Oct 10
|
Indivior Shares Fall Pre-Bell After Lowering Fiscal Year 2024 Revenue Outlook
|
|
Oct 10
|
Indivior Provides Preliminary Q3 2024 Results; Updates FY 2024 Guidance; Group Continues to Expect SUBLOCADE Peak Net Revenue of >$1.5 Billion
|
|
Oct 7
|
Indivior's SUBLOCADE® Rapid Induction/Alternative Injection Site Prior Approval Supplement (PAS) Receives FDA Priority Review
|
|
Oct 1
|
Addex Therapeutics Ltd (ADXN) Q2 2024 Earnings Call Transcript Highlights: Key Financials and ...
|
|
Sep 25
|
Rigel (RIGL) Surges 19.7%: Is This an Indication of Further Gains?
|
|
Sep 4
|
Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder
|